[急性白血病中凝血因子 XIII 替代治疗：一项随机对照研究的结果]

[Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study].

作者信息

Rasche H, Haghou F, Gaus W, Dietrich M, Hoelzer D, Pflieger H, Kurrle E, Pindur G, Seifried E, Heimpel H

出版信息

Dtsch Med Wochenschr. 1982 Dec 10;107(49):1882-6. doi: 10.1055/s-2008-1070225.

DOI:10.1055/s-2008-1070225

Abstract

A randomized and controlled study was undertaken to test whether substitution with factor XIII concentrates influences the clinical course in patients with acute leukaemia and acquired factor XIII deficiency (less than or equal to 60%). A control group of 31 patients was compared with a factor XIII-treated group of 29 patients. Partial factor XIII deficiency was successfully corrected by substitution. On the other hand, there was no statistically significant difference between the two patient groups in the frequency and severity of bleeding complications, transfusion requirements, and the number of remissions. Undesirable side-effects as a result of substitution treatment were not observed.

摘要

开展了一项随机对照研究，以测试用凝血因子 XIII 浓缩物替代治疗是否会影响急性白血病和获得性凝血因子 XIII 缺乏症（小于或等于60%）患者的临床病程。将31例患者的对照组与29例接受凝血因子 XIII 治疗的患者组进行比较。通过替代治疗成功纠正了部分凝血因子 XIII 缺乏症。另一方面，两组患者在出血并发症的频率和严重程度、输血需求以及缓解次数方面没有统计学上的显著差异。未观察到替代治疗产生的不良副作用。